Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totaling 395,021 shares, a decrease of 38.3% from the April 15th total of 640,470 shares. Based on an average daily volume of 241,206 shares, the short-interest ratio is presently 1.6 days. Approximately 2.9% of the company’s shares are short sold.
Insider Buying and Selling
In related news, CEO Matthew Angel purchased 231,482 shares of the company’s stock in a transaction that occurred on Tuesday, March 24th. The stock was purchased at an average price of $2.16 per share, with a total value of $500,001.12. Following the completion of the transaction, the chief executive officer owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.28% of the company’s stock.
Institutional Investors Weigh In On Tempest Therapeutics
Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Tempest Therapeutics by 20.8% during the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after purchasing an additional 27,952 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Tempest Therapeutics during the 4th quarter valued at $33,000. Finally, Sabby Management LLC acquired a new stake in Tempest Therapeutics during the 4th quarter valued at $513,000. 22.52% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
View Our Latest Analysis on TPST
Tempest Therapeutics Stock Down 12.4%
Shares of Tempest Therapeutics stock traded down $0.26 during trading hours on Friday, hitting $1.83. The company’s stock had a trading volume of 270,577 shares, compared to its average volume of 173,402. Tempest Therapeutics has a 1-year low of $1.50 and a 1-year high of $12.23. The business has a fifty day moving average of $1.94 and a 200 day moving average of $3.35. The company has a market capitalization of $26.25 million, a PE ratio of -0.30 and a beta of -1.75.
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($2.25). On average, sell-side analysts anticipate that Tempest Therapeutics will post -1.34 earnings per share for the current fiscal year.
Tempest Therapeutics Company Profile
Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.
The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.
Read More
- Five stocks we like better than Tempest Therapeutics
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
